Identification of circRBM39 as a tumor suppressor in breast cancer
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA1224764 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR32369873_1.fastq.gz | Fastqsanger.gz | |||
| SRR32369873_2.fastq.gz | Fastqsanger.gz | |||
| SRR32369874_1.fastq.gz | Fastqsanger.gz | |||
| SRR32369874_2.fastq.gz | Fastqsanger.gz | |||
| SRR32369875_1.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 16 |
Similar Datasets
Project description:MEF2D functions as a tumor suppressor in breast cancer
| PRJNA1109388 | ENA
Project description:In this study, we identify leucyl-tRNA synthetase (LARS) as a breast tumor suppressor. To identify the mechanism underlying LARS-mediated breast tumor suppression, we conducted TMT-proteomics in PyMT mouse tumors with monoallelic genetic deletion of LARS in the mammary tumor compartment. The analyses implicate LARS as a regulator of leucine-rich protein translation resulting in downregulation of candidate leucine-rich tumor suppressor genes.
2022-01-10 | PXD026609 | Pride
Project description:The transcription factor c-Myb has been well characterized as an oncogene in several human tumor types, and its expression in the hematopoietic stem/progenitor cell population is essential for proper hematopoiesis. However, the role of c-Myb in mammopoeisis and breast tumorigenesis is poorly understood, despite its high expression in the majority of breast cancer cases (60-80%). We find that c-Myb high expression in human breast tumors correlates with the luminal/ER+ phenotype and a good prognosis. RNAi knock-down of endogenous c-Myb levels in the MCF7 luminal breast tumor cell line increases tumorigenesis both in vitro and in vivo, suggesting a tumor suppressor role in luminal breast cancer. We created a mammary-derived c-Myb expression signature and found it to be highly correlated with a published mature luminal mammary cell signature and least correlated with a mammary stem/progenitor lineage gene signature. These data describe, for the first time, a tumor suppressor role for the c-Myb proto-oncogene in breast cancer that has implications for understanding luminal tumorigenesis and for guiding treatment. refXsample
2010-10-15 | E-GEOD-21371 | biostudies-arrayexpress
Project description:Circular RNAs (circRNAs) have emerged as pivotal players in both physiology and human cancers. However, their modes of action in breast cancer remain elusive. Herein, we have identified a significantly downregulated circRNA, termed circRBM39, in breast cancer specimen compared with adjacent non-tumor tissues. Gain- and loss-of-function assays demonstrate that circRBM39 inhibits breast tumorigenesis through the impairment of DNA damage response in vitro and in vivo. Mechanistically, circRBM39 directly interacts with replication protein A2 (RPA2) and decreases the RPA2 protein level via facilitating the HERC2-mediated ubiquitination, thereby disrupting homologous recombination repair. Importantly, administration of in vitro synthesized circRBM39 exhibits substantially repressive effects on breast cancer progression, sensitizes breast cancer cells to PARP inhibition, and renders them susceptible to synthetic lethality in a subcutaneous breast tumorigenesis model. Collectively, our findings demonstrate the tumor-suppressive roles of circRBM39 in breast cancer, and highlight the interplay between circRNA and genome stability in cancers.
2025-02-22 | GSE289776 | GEO
Project description:The myocyte enhancer factor 2 (MEF2) gene family plays fundamental roles in the genetic programs that control cell differentiation, morphogenesis, proliferation, and survival in a wide range of cell types. The molecular programs they regulate and their role in tumor development and progression remain incompletely understood. The present study evaluated whether the MEF2D transcription factor functions as a tumor suppressor in breast cancer. We found knockout of the MEF2D gene in mouse mammary epithelial cells resulted in phenotypic changes characteristic of neoplastic transformation, including: enhanced cell proliferation, loss of contact inhibition, and anchorage-independent growth in soft agar, as well as capacity for tumor development in mice. Through RNAseq analysis, we found knockout of MEF2D induced the epithelial-to-mesenchymal transition (EMT) and activated several oncogenic signaling pathways. In summary, our study indicates that MEF2D may be a putative tumor suppressor, acting through selective gene regulatory programs that have clinical and therapeutic significance in breast cancer.
2025-05-08 | GSE267037 | GEO
Project description:BACKGROUND: The transcription factor c-Myb has been well characterized as an oncogene in several human tumor types, and its expression in the hematopoietic stem/progenitor cell population is essential for proper hematopoiesis. However, the role of c-Myb in mammopoeisis and breast tumorigenesis is poorly understood, despite its high expression in the majority of breast cancer cases (60-80%). METHODOLOGY/PRINCIPAL FINDINGS: We find that c-Myb high expression in human breast tumors correlates with the luminal/ER+ phenotype and a good prognosis. Stable RNAi knock-down of endogenous c-Myb in the MCF7 luminal breast tumor cell line increased tumorigenesis both in vitro and in vivo, suggesting a possible tumor suppressor role in luminal breast cancer. We created a mammary-derived c-Myb expression signature, comprised of both direct and indirect c-Myb target genes, and found it to be highly correlated with a published mature luminal mammary cell signature and least correlated with a mammary stem/progenitor lineage gene signature. CONCLUSIONS/SIGNIFICANCE: These data describe, for the first time, a possible tumor suppressor role for the c-Myb proto-oncogene in breast cancer that has implications for the understanding of luminal tumorigenesis and for guiding treatment.
2010-10-15 | GSE21371 | GEO
Project description:To investigate the role of FLRT2 in breast cancer, its expression was knocked down and upregulated in mammary cell lines. Our results show that FLRT2 has tumor suppressor activity in breast cancer.
2016-12-30 | GSE85247 | GEO
Project description:Transposon mutagenesis screens in mice has allowed us the identification of new tumor suppressor genes in cancer. To further explore the mechanistic role of these genes at the molecular level, we decided to study the transcriptome of human immortalized and cancer cells which underwent siRNA-mediated silencing of these tumor suppressors. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/
2016-02-17 | E-ERAD-432 | biostudies-arrayexpress
Project description:ECRG4 is a promising tumor suppressor gene (TSG) recently identified in esophageal carcinoma. Its expression and prognostic value have never been explored in breast cancer. Using DNA microarray, we examined ECRG4 mRNA expression in 353 invasive breast cancer samples. A meta-analysis was performed on a large public retrospective gene expression dataset (n=1,387) to analyze correlation between ECRG4 expression and histo-clinical features including survival.
2011-12-02 | GSE31448 | GEO
Project description:Alteration of metabolism in cancer cells is a central aspect of the mechanisms that sustain aggressive traits. Aldo-keto reductase 1 B1 (AKR1B1) catalyzes the reduction of several aldehydes to alcohols consuming NADPH. Nevertheless, the ability of AKR1B1 to reduce different substrates renders difficult to comprehensively ascertain its biological role. Recent evidence has implicated AKR1B1 in cancer, however, the mechanisms underlying its pro-oncogenic function remain largely unknown. In this work, we report that AKR1B1 expression is controlled by the p53 tumor suppressor. We found that breast cancer patients bearing wild type TP53 have reduced AKR1B1 expression. In cancer cell lines, p53 reduced AKR1B1 mRNA and protein levels, and repressed promoter activity in luciferase assays. Furthermore, chromatin immunoprecipitation assays indicated that p53 is recruited to the AKR1B1 promoter. We also observed that AKR1B1 overexpression promoted metastasis in the 4T1 orthotopic model of triple negative breast cancer. Proteomic analysis of 4T1 cells overexpressing AKR1B1 showed that AKR1B1 exerts a marked effect on proteins related to metabolism, with particular impact on mitochondrial function. This work provides novel insights on the link between the p53 pathway and metabolism in cancer cells and contributes to characterizing the alterations associated to the pathologic role of AKR1B1.
2023-09-19 | PXD045048 | Pride